← Leaderboards
Bin Chen
University Of California, San Francisco
$5,048,082
Attributed
$6,274,923
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,274,923 · 6
By mechanism
R01$4,432,871 · 2
K01$681,707 · 1
R21$559,733 · 1
R61$542,402 · 1
OT2$58,210 · 1
Top collaborators
- Jiayu Zhou6 shared
- Xiaopeng Li1 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Rita Mukhtar$1,277,220
- Jeremy O Jones$1,300,147
- Wensha Yang$2,009,718
- Robert Laird Judson-Torres$4,354,929
- Felicia C. Chow$4,973,965
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsCell LineGene ExpressionMolecularData SetPrimary Carcinoma Of The Liver CellsScientistNovel TherapeuticsGene Expression ProfilePre-Clinical ModelSamplingTherapeutic CandidateGenesDrug EfficacyMouse ModelCostDrug CandidateDiffuse Intrinsic Pontine GliomaDrug ScreeningBaseOverexpressionComputing MethodologiesGenerationsCancer Cell Line
Grant awards (23)
Screening of novel compounds through the reversal of gene expression in idiopathic pulmonary fibrosis$542,402
R61 · FY2025 · HL
virtual compound screening using gene expression$420,807
R01 · FY2025 · GM · contact PI
virtual compound screening using gene expression$420,807
R01 · FY2024 · GM · contact PI
Research Supplement to Promote Diversity for R01GM145700$124,874
R01 · FY2024 · GM · contact PI
virtual compound screening using gene expression$420,807
R01 · FY2023 · GM · contact PI
Repurpose open data to discover therapeutics for understudied diseases$418,252
R01 · FY2023 · GM · contact PI
Repurpose open data to discover therapeutics for understudied diseases$346,747
R01 · FY2023 · GM · contact PI
Equipment Purchases for R01GM145700$103,178
R01 · FY2023 · GM · contact PI
virtual compound screening using gene expression$420,807
R01 · FY2022 · GM · contact PI
Repurpose open data to discover therapeutics for understudied diseases$415,179
R01 · FY2022 · GM · contact PI
Repurpose open data to discover therapeutics for understudied diseases$51,175
R01 · FY2022 · GM · contact PI
Repurpose open data to discover therapeutics for understudied diseases$6,396
R01 · FY2022 · GM · contact PI
Repurpose open data to discover therapeutics for understudied diseases$416,266
R01 · FY2021 · GM · contact PI
Repurpose open data to discover therapeutics for understudied diseases$413,916
R01 · FY2020 · GM · contact PI
Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers$169,087
K01 · FY2020 · ES · contact PI
Drug biomarker resources for precise translational research$58,210
OT2 · FY2020 · TR · contact PI
Repurpose open data to discover therapeutics for understudied diseases$453,660
R01 · FY2019 · GM · contact PI
Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers$170,187
K01 · FY2019 · ES · contact PI
Targeting glucose metabolism for the treatment of Hepatocellular Carcinoma$267,711
R21 · FY2018 · TR · contact PI
Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers$171,217
K01 · FY2018 · ES · contact PI
Targeting glucose metabolism for the treatment of Hepatocellular Carcinoma$183,400
R21 · FY2017 · TR · contact PI
Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers$171,216
K01 · FY2017 · ES · contact PI
Targeting glucose metabolism for the treatment of Hepatocellular Carcinoma$108,622
R21 · FY2017 · TR · contact PI